



Indicator Analysis 2026

Annual Report of the Certified Breast Cancer Centres

Audit year 2025 / Indicator year 2024

Table of Content

Introduction	3
General Information	3
Status of the certification system: Breast Cancer Centre 2025	5
Clinical sites taken into account	6
Tumour documentation systems in the centre's clinical sites	7
Basic data	8
Analysis of indicator.....	12
Indicator No 1: Post-operative tumour board	12
Indicator No 2: Pretherapeutic tumour board	13
Indicator No 3: Tumour board local recurrence/metastases	14
Indicator No 4: Radiotherapy after BCT in the case of invasive breast cancer (GL QI)	15
Indicator No 5: Radiotherapy after BCT in the case of DCIS	16
Indicator No 6: Chemotherapy in the case of rec. pos. and nodal pos. result	17
Indicator No 7: Endocrine therapy in the case of steroid rec. positive result (GL QI)	18
Indicator No 8: Trastuzumab therapy over 1 year in case of HER-2 pos. result (GL QI)	19
Indicator No 9: Endocrine therapy for metastasis (GL QI)	20
Indicator No 10: Psycho-oncological distress screening	21
Indicator No 11: Social service counselling	22
Indicator No 12: Patients enrolled in a study	23
Indicator No 13: Pretherapeutic histological confirmation (GL QI)	26
Indicator No 14a: Primary cases breast cancer	27
Indicator No 14b: Patients with 1st (local) recurrence and/or distant metastasis (without primary M1 patients)	28
Indicator No 15: Number of surgical procedures for R0-resection for BCT.....	29
Indicator No 16: Breast-conserving procedure for pT1 (incl. (y)pT1 u. (y)pT0)	30
Indicator No 17: Mastectomies	31
Indicator No 18: Lymph node removal in the case of DCIS (GL QI)	32
Indicator No 19: Determination of nodal status in case of invasive breast cancer	33
Indicator No 20a: Only sentinel lymphonodectomy (SLNE) for pN0 (women) (GL QI)	34
Indicator No 20b: Only sentinel lymphonodectomy (SLNE) for pN0 (men) (GL QI)	35
Indicator No 21: Intraoperative sample radiography / sonography (GL QI)	36
Indicator No 22: Revision surgeries	37
Indicator No 23: Therapy of the axillary lymphatic drainage for pN1mi (GL QI)	38
Imprint.....	39

General information

Indicator No 4:	Radiotherapy after BCT in the case of invasive breast cancer (GL QI)
Indicator No 5:	Radiotherapy after BCT in the case of DCIS
Indicator No 6:	Chemotherapy in the case of rec. pos. and nodal pos. result
Indicator No 7:	Endocrine therapy in the case of steroid rec. positive result (GL QI)
Indicator No 8:	Trastuzumab therapy over 1 year in case of HER-2 pos. result (GL QI)
Indicator No 9:	Endocrine therapy for metastasis (GL QI)
Indicator No 10:	Psycho-oncological distress screening

Quality indicators of the guidelines (GL QI):

In the table of contents and in the respective headings, the indicators which correspond to the quality indicators of the evidence-based guidelines are specifically identified. These quality indicators are based on the strong recommendations of the guidelines and were derived from the guidelines groups in the context of the German Guideline Programme in Oncology (GGPO). Further information: www.leitlinienprogramm-onkologie.de.

The quality indicators (QIs) relate to version 4.4 of the S3-GL ‘Early detection, diagnosis, treatment and follow-up care for breast cancer’.

	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Primary cases of the denominator in which radiotherapy was recommended	107*	28 - 637	40,064	38,714
Denominator	Primary cases with an invasive breast cancer and BCT (without primary M1 pat.)	109*	29 - 677	40,995	39,583
Rate	Target value ≥ 90%	98.4%	90.1% - 100%	97.7%**	97.8%

Basic data indicator:

The definition of the **numerator**, **denominator** and the **target value** are taken from the data sheet.

The **median** for numerator and denominator does not refer to an existing centre but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

Range specifies the value range for the numerator, denominator and ratio of all centres.

The column **Patients Total** displays the total of all patients treated according to the indicator and the corresponding quota.





Diagram:

The x-axis indicates the number of centres and the y-axis represents the values in percent or number (e.g. primary cases). The target value is depicted as a green horizontal line. The median, which is also depicted as a green horizontal line, divides the entire group into two equal halves.


*For further information on the methodological approach see „Development of guideline-based quality indicators” (https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Methodik/QIEP_OL_Version2_english.pdf)

General Information



Cohort development:

The **cohort development** in the years **2020, 2021, 2022, 2023** and **2024** is presented in a box plot diagram.



Boxplot:

A box plot consists of a **box with median**, **whiskers** and **outliers**. 50 percent of the centres are within the box. The median divides the entire available cohort into two halves with an equal number of centres. The whiskers and the box encompass a 90th percentile area/range. The extreme values are depicted here as dots.

Status of the certification system: Breast Cancer Centres 2025


	31.12.2025	31.12.2024	31.12.2023	31.12.2022	31.12.2021	31.12.2020
Ongoing certification procedures	9	9	11	4	5	4
Certified Centres	272	268	257	254	248	245
Certified clinical sites	296	293	289	288	286	284
BCC with 1 clinical site	251	246	229	224	214	210
2 clinical sites	19	20	26	28	32	33
3 clinical sites	1	1	0	0	0	0
4 clinical sites	1	1	2	2	2	2

Clinical sites taken into account

	Sites DKG & NRW	DKG Breast Cancer Centres					
	31.12.2025	31.12.2025	31.12.2024	31.12.2023	31.12.2022	31.12.2021	31.12.2020
Sites included in the Annual Report	314	290	290	284	282	280	280
Correspond to	-	98.0%	98.9%	98.3%	97.9%	97.9%	98.6%
Primary cases total*	76,819	70,523	67,656	63,441	62,100	58,331	60,752
Primary cases per site (mean)*	245	243	233	223	220	208	217
Primary cases per site (median)*	203.5	202.5	197.5	185.5	184	180	182
Breast Cancer Centres North Rhine-Westphalia (NRW)	31.12.2025	This Annual Report looks at the Breast Cancer Centres certified in the certification system of the German Cancer Society (DKG) and, from 2021, Breast Centres in the state of NRW that participate in the DKG's data management system. The basis for the diagrams in the annual report is the data sheet. The indicators published here refer to the indicator year 2024. They represent the assessment basis for the audits carried out in 2025. <u>DKG Breast Cancer Centres:</u> The Annual Report includes 290 of the 296 DKG-certified centre sites. Excluded are 6 clinical sites that were certified for the first time in 2025 (data mapping of complete calendar year not mandatory for first-time certifications). <u>Breast Cancer Centres NRW:</u> Included in the Annual Report are 24 clinical sites in the state of NRW that participate in the DKG's data management. A total of 6,296 primary cases of breast cancer were treated at the 24 clinical sites. A current overview of all sites is shown at www.oncomap.de. Using the filter "Certificate", a common view or a view separated according to certified and recognised sites can be selected.					
Sites considered in the Annual Report	24						
Primary cases total*	6,296						
Primary cases per site (mean)*	262						
Primary cases per site (median)*	225						

*The figures are based on the clinical sites listed in the Annual Report.

Tumour documentation systems in the centre's clinical sites




Andere = other
Eigenentwicklung = Intrinsic development
Tumorzentrum = Tumour centre
Tumordokumentation = Tumour documentation

Legend:	
Others	System used in < 4 clinical sites

The details on the tumour documentation system was taken from the Data Sheet (Basic Data Sheet). It is not possible to use more than one system. In many cases, support is provided by the cancer registries or there may be a direct link to the cancer registry via a specific tumour documentation system.


Basic data – Primary Cases Breast Cancer



	Tis (=DCIS), N0, M0	T1, N0, M0	T2, N0, M0	T3, N0, M0	T4, N0, M0	N+ (every T incl. Tis/Tx), M0)	M1 (every N, every T incl. Tis/Tx)	Not assignable*	Total
Non-surgical primary cases	240 (3.2%)	2,142 (7.3%)	2,303 (15.7%)	213 (17.4%)	405 (47.2%)	2,716 (15.7%)	4,490 (86.2%)	120 (13.7%)	12,629
Primary cases surgery with neoadj. Th.**	96 (1.3%)	6,319 (21.6%)	5,127 (35.0%)	348 (28.4%)	207 (24.1%)	5,555 (32.0%)	272 (5.2%)	173 (19.8%)	18,097
Primary cases surgery without neoadj. Th.***	7,087 (95.5%)	20,771 (71.1%)	7,222 (49.3%)	665 (54.2%)	246 (28.7%)	9,078 (52.3%)	444 (8.5%)	580 (66.4%)	46,093
Primary cases Total	7,423	29,232	14,652	1,226	858	17,349	5,206	873	76,819

* others: e.g. T1, N0, Mx
** primary cases operated with neo-adjuvant or pre-operative systemic therapy
*** primary cases operated without neo-adjuvant or pre-operative systemic therapy


Basic data – Distribution of surgically treated primary cases



	Tis (=DCIS), NO, M0	T1, NO, M0	T2, NO, M0	T3, NO, M0	T4, NO, M0	N+ (every T incl. Tis/Tx), M0)	M1 (every N, every T incl. Tis/Tx)	Not assignable*	Total
Mastectomies	1,524 (21.2%)	3,771 (13.9%)	3,511 (28.4%)	679 (67.0%)	339 (74.8%)	6,243 (42.7%)	466 (65.1%)	178 (23.6%)	16,711
BCT	5,659 (78.8%)	23,319 (86.1%)	8,838 (71.6%)	334 (33.0%)	114 (25.2%)	8,390 (57.3%)	250 (34.9%)	575 (76.4%)	47,479
Surgically treated Primary cases Total	7,183	27,090	12,349	1,013	453	14,633	716	753	64,190


* Not assignable: e.g. T1, N0, Mx

Basic data




	Female patients	Male patients	Primary cases Total
unilateral	71,765 (97.0%)	628 (99.4%)	72,393
bilateral (simultaneous)	2,209 (3.0%)	4 (0.6%)	4,426
			76,819
Total	73,974	632	

Basic data – Ratio of primary cases to recurrences / metastases breast cancer




Primary cases	Patients with new (local) recurrence and/ or distant metastases (without primary M1 patients)	Centre Cases
76,819 (84.8%)	13,718 (15.2%)	90,537 (100%)

1. Post-operative tumour board



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Primary cases of denominator presented in the postoperative tumour board	169*	53 – 1,114	63,833	61,313
Denominator	Surgical primary cases (primary case definition see 1.2.0a)	169*	54 – 1,134	64,190	61,675
Rate	Target value ≥ 95%	100%	83.5% - 100%	99.4%**	99.4%




	2020	2021	2022	2023	2024
Max	100%	100%	100%	100%	100%
95 th percentile	100%	100%	100%	100%	100%
75 th percentile	100%	100%	100%	100%	100%
Median	100%	100%	100%	100%	100%
25 th percentile	99.0%	99.1%	99.2%	99.3%	99.4%
5 th percentile	97.1%	97.3%	97.8%	97.1%	97.3%
Min	95.5%	95.1%	77.4%	95.1%	83.5%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
314	100%	312	100%	313	99.7%	312	100%
Comments: Post-operative presentation at the tumour board has been carried out to a high degree for many years (median 100%). Of the 314 primary cases that underwent surgery, 201 were presented post-operatively at the tumour board. One centre falls short of the target value.							


*The median for numerator and denominator does not refer to an existing centre but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

** Percentage of total patients treated in centres according to the numerator.

2. Pretherapeutic tumour board



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Primary cases of denominator presented in the pretherapeutic tumour board	164*	46 – 1,114	63,492	59,835
Denominator	Primary cases	203.5*	68 – 1,213	76,819	73,505
Rate	Target value ≥ 40%	93.3%	37% - 100%	82.7%**	81.4%




	2020	2021	2022	2023	2024
Max	100%	100%	100%	100%	100%
95 th percentile	100%	100%	100%	100%	100%
75 th percentile	97.2%	97.5%	98.1%	98.4%	98.5%
Median	86.0%	90.0%	92.4%	91.8%	93.3%
25 th percentile	59.6%	61.3%	62.2%	64.4%	69.2%
5 th percentile	42.9%	41.2%	42.6%	43.2%	48.0%
Min	12.3%	13.9%	13.2%	22.7%	37.0%


Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
314	100%	312	100%	312	99.4%	305	97.8%
Comments: Just under 83% of primary cases were presented to the pretherapeutic tumour board. At 31 out of 314 clinical sites, 100% of primary cases were presented pretherapeutic. Two centres fell short of the target value of ≥ 40%. Both centres have taken steps to achieve the target value.							

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centres according to the numerator.

3. Tumour board local recurrence/metastases



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Nominator	Patients of the dominator presented in the tumour board	33.5*	2 - 209	13,049	12,312
Denominator	Patients with first (local) recurrence and/or first distant metastasis (= Indicator 14b) (without primary M1 pat.)	35*	2 - 209	13,718	12,976
Rate	Mandatory justification*** <70%	100%	34.3% - 100%	95.1%**	94.9%




	2020	2021	2022	2023	2024
Max	100%	100%	100%	100%	100%
95 th percentile	100%	100%	100%	100%	100%
75 th percentile	100%	100%	100%	100%	100%
Median	96.9%	98.7%	98.2%	99.6%	100%
25 th percentile	90.3%	90.3%	91.6%	92.3%	93.5%
5 th percentile	77.8%	78.7%	75.0%	77.6%	81.8%
Min	61.5%	70.0%	63.9%	67.4%	34.3%

Clinical sites with evaluable data				Clinical sites meeting the plausibility limits			
2024		2023		2024		2023	
314	100%	312	100%	311	99%	309	99%


Comments:
Around 95% of patients with a first (local) recurrence and/or first distant metastases were presented at the tumour board. At around half of the clinical sites (159 out of 314), all patients in the population under consideration were presented at the tumour board. Three centres achieved a rate < 70% and were required to make a mandatory justification. The centres organised training sessions and quality circles to raise staff awareness. At one centre, patients were presented at the oncologists' tumour board.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centres according to the numerator
*** For values outside the plausibility limit(s), the centres are required to provide a justification..

4. Radiotherapy after BCT in the case of invasive breast cancer (GL QI)



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Primary cases of the denominator in which radiotherapy was recommended	107*	28 - 637	40,064	38,714
Denominator	Primary cases with an invasive breast cancer and BCT (without primary M1 pat.)	109*	29 - 677	40,995	39,583
Rate	Target value ≥ 90%	98.4%	90.1% - 100%	97.7%**	97.8%




		2020	2021	2022	2023	2024	Clinical sites with evaluable data		Clinical sites meeting the target value			
							2024	2023	2024	2023	2024	2023
	Max	100%	100%	100%	100%	100%						
	95 th percentile	100%	100%	100%	100%	100%	314	100%	312	100%	314	100%
	75 th percentile	100%	99.5%	100%	100%	99.4%						
	Median	98.3%	98.5%	98.3%	98.4%	98.4%						
	25 th percentile	96.2%	96.5%	96.5%	96.7%	96.5%						
	5 th percentile	92.0%	92.8%	92.5%	92.8%	92.7%						
	Min	85.9%	90.1%	90.0%	90.0%	90.1%						

Comments:


This quality indicator from the guideline shows a high level of compliance across the centres. The median for this indicator has stood at >98% for several years. As in the previous year, radiotherapy was recommended for just under 98% of all primary cases of invasive breast cancer treated with BCT (excluding primary M1 patients).

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centres according to the numerator.

5. Radiotherapy after BCT in the case of DCIS



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Primary cases of the denominator in which radiotherapy was initiated	11*	0 - 73	4,413	4,238
Denominator	Primary cases with DCIS and BCT	15*	1 - 106	5,626	5,405
Rate	Mandatory justification*** <80%	83.3%	0% - 100%	78.4%**	78.4%




		2020	2021	2022	2023	2024
Max		100%	100%	100%	100%	100%
95 th percentile		100%	100%	100%	100%	100%
75 th percentile		92.7%	90.0%	91.7%	90.0%	90.5%
Median		84.4%	82.4%	82.5%	81.8%	83.3%
25 th percentile		74.6%	72.7%	69.2%	69.3%	71.0%
5 th percentile		41.9%	45.0%	50.0%	42.5%	50.0%
Min		0.0%	0.0%	25.0%	0.0%	0.0%


Clinical sites with evaluable data				Clinical sites within the plausibility limits			
2024		2023		2024		2023	
314	100%	310	99.4%	194	61.8%	182	58.7%
Comments: Radiotherapy was initiated in approximately 78% of primary cases of DCIS treated with breast-conserving therapy. This indicator had been discussed at the Commission's 2025 meeting, and the Commission had recommended that, from the 2026 audit year onwards, the indicator be recorded with a plausibility threshold of < 60%, as the indications for radiotherapy following surgical treatment of DCIS had changed and an increasing trend towards de-escalation was expected in this area.							

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centres according to the numerator
*** For values outside the plausibility limit(s), the centres are required to provide a justification..

6. Chemotherapy in the case of receptor pos. and nodal pos. result



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Primary cases of the denominator in which chemotherapy was recommended	23*	6 - 127	8,317	8,374
Denominator	Primary cases with invasive breast cancer with receptor positive and nodal positive result (without primary M1 pat.)	38*	10 - 191	13,627	13,777
Rate	Mandatory justification*** < 60%	61.5%	18.2% - 100%	61%**	60.8%




		2020	2021	2022	2023	2024	Clinical sites with evaluable data				Clinical sites within the plausibility limits			
	Max	100%	100%	100%	98.2%	100%	2024		2023		2024		2023	
	95 th percentile	85.7%	84.5%	84.5%	84.5%	85.3%	314	100%	312	100%	185	58.9%	178	57.1%
	75 th percentile	72.2%	70.6%	69.0%	69.0%	69.8%								
	Median	65.5%	63.2%	62.0%	61.3%	61.5%								
	25 th percentile	58.5%	56.1%	53.9%	51.0%	51.8%								
	5 th percentile	43.8%	39.5%	41.2%	36.4%	35.2%								
	Min	27.3%	21.7%	12.5%	18.8%	18.2%								
Comments: Chemotherapy was recommended for 61% of primary cases of invasive breast cancer with receptor positive and nodal positive result (excluding primary M1 patients) (range 18–100%). At the 2025 meeting of the Certification Commission, it was decided to remove this indicator due to changes in recommendations/guidelines, gene expression profiles and therapies involving CDK4/6 inhibitors. The indicator is therefore reported here for the last time.														

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.


** Percentage of total patients treated in centres according to the numerator

*** For values outside the plausibility limit(s), the centres are required to provide a justification..

7. Endocrine therapy in the case of steroid rec. positive result (GL QI)



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Primary cases of the denominator in which endocrine therapy was recommended	139*	24 - 808	51,511	49,671
Denominator	Primary cases with invasive breast cancer in the case of steroid rec. positive result (without primary M1 pat.)	142*	24 - 837	53,103	51,302
Rate	Target value ≥ 95%	97.2%	79.2% - 100%	97%**	96.8%




		2020	2021	2022	2023	2024
●	Max	100%	100%	100%	100%	100%
	95 th percentile	100%	100%	100%	100%	100%
	75 th percentile	97.7%	98.8%	98.9%	98.8%	98.8%
	Median	95.2%	97.2%	97.2%	97.4%	97.2%
	25 th percentile	90.9%	95.8%	95.7%	95.7%	95.9%
	5 th percentile	84.8%	90.0%	90.9%	91.2%	92.2%
●	Min	79.8%	82.5%	83.3%	81.2%	79.2%


Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
314	100%	312	100%	284	90.5%	264	84.6%
Comments: Endocrine therapy was recommended for 97% of primary cases of invasive breast cancer with a steroid rec. positive result (excluding primary M1). The target value for this indicator is ≥ 95% and was met by ~91% of the centres. 30 centres have a rate of < 95%. Compared with the previous indicator year, there has been an increase from ~85% to ~91% in the proportion of centres meeting the target value. Reasons for non-compliance included: ongoing neoadjuvant therapy/pending post-operative tumour sampling (28x), only weak hormone receptor positivity and/or advanced age/contraindications or comorbidities (14x), and documentation issues (1x).							

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centres according to the numerator.

8. Trastuzumab therapy over 1 year in the case of HER-2 pos. result (GL QI)



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Primary cases of the denominator for which trastuzumab therapy over 1 year was recommended	16*	3 - 95	6,009	5,834
Denominator	Primary cases with invasive breast cancer with HER-2 pos. result ≥ pT1c (in neoadj. pre-treated and in non-operated patients: ≥ cT1c) (without primary M1 patients)	17*	3 - 95	6,306	6,139
Rate	Target value ≥ 95%	100%	42.9% - 100%	95.3%**	95%




	2020	2021	2022	2023	2024
Max	100%	100%	100%	100%	100%
95 th percentile	100%	100%	100%	100%	100%
75 th percentile	100%	100%	100%	100%	100%
Median	99.0%	97.3%	100%	97.0%	100%
25 th percentile	90.5%	91.7%	92.9%	91.7%	92.9%
5 th percentile	77.0%	79.2%	80.0%	79.6%	77.8%
Min	62.5%	60.0%	42.1%	58.3%	42.9%


Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
314	100%	312	100%	217	69.1%	196	62.8%
Comments: In approximately 95% of primary cases of invasive HER2-positive breast cancer ≥ pT1c (in neoadj. pre-treated and in non-operated patients ≥ cT1c) (excluding primary M1) were recommended to receive trastuzumab therapy for 1 year. 69% of clinical sites met the target value; 97 centres had a rate of < 95%. The most common reason given was that, due to existing comorbidities (particularly cardiac conditions), limited treatment options or advanced age, the recommendation was not followed (87x). Another reason cited was that treatment was still pending (6x).							

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centres according to the numerator.

9. Endocrine therapy for metastasis (GL QI)



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Patients of the denominator, who were started on endocrine based therapy in the metastasised stage as first-line therapy	14*	1 - 79	5,255	4,914
Denominator	Patients with steroid rec. pos. and HER2-negative inv. breast cancer with 1st Remote metastasis (incl. primary M1 pat.)	16*	1 - 79	5,866	5,495
Rate	Target value $\geq 95\%$	92.9%	45.5% - 100%	89.6%**	89.4%




		2020	2021	2022	2023	2024	Clinical sites with evaluable data		Clinical sites meeting the target value			
							2024	2023	2024	2023	2024	2023
	Max	100%	100%	100%	100%	100%	312	99.4%	310	99.4%	130	41.7%
	95 th percentile	100%	100%	100%	100%	100%					137	44.2%
	75 th percentile	97.7%	100%	100%	100%	100%						
	Median	88.2%	91.1%	90.0%	92.9%	92.9%						
	25 th percentile	76.5%	81.4%	80.0%	83.3%	83.3%						
	5 th percentile	52.9%	62.6%	63.6%	61.7%	69.0%						
	Min	10.0%	40.0%	0.0%	48.3%	45.5%						
Comments: Data from 312 of the 314 clinical sites were analysed for this indicator. At 2 clinical sites, none of the patients included in the denominator were treated. In just under 90% of patients with steroid rec. pos and HER2-negative inv. breast cancer with 1st Remote metastasis (including primary M1 patients), endocrine-based therapy was initiated at the metastatic stage as first-line treatment. Approximately 42% of the clinical sites met the target value, whilst 182 clinical sites had a rate < 95%. In the vast majority of audits, the results were found to be plausible.												


*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

** Percentage of total patients treated in centres according to the numerator.

10. Psycho-oncological distress screening




	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Patients of the denominator who were psycho-oncologically screened	175*	0 - 1004	65,087	44,665
Denominator	Primary case pat. (= indicator 14a) + patients with new (local) recurrence and/or distant metastases (= indicator 14b) (without primary M1 patients, as already included in the primary cases)	237*	100 – 1,361	90,393	66,737
Rate	Target value ≥ 65%	74%	0% - 100%	72%**	66.9%




		2020	2021	2022	2023	2024	Clinical sites with evaluable data		Clinical sites meeting the target value			
							2024	2023	2024	2023	2024	2023
	Max	----	----	----	100%	100%	313	99.7%	248	79.5%	255	81.5%
	95 th percentile	----	----	----	92.9%	92.3%					177	71.4%
	75 th percentile	----	----	----	80.7%	82.4%						
	Median	----	----	----	71.4%	74.0%						
	25 th percentile	----	----	----	61.1%	66.8%						
	5 th percentile	----	----	----	23.7%	42.4%						
	Min	----	----	----	0.0%	0.0%						
Comments: 72% of the patients included in the denominator underwent a psycho-oncological distress screening. The indicator shows a wide range from 0 to 100%. In approximately 82% of clinical sites, the target value has been met (previous indicator year's: 72%). Reasons cited included challenges in implementing the screening, difficulties in accurately recording the patients screened, and patients declining the screening.												

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centres according to the numerator.

11. Social service counselling



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Patients of the denominator who received counselling by social services in an in- or outpatient setting	169*	3 – 1,088	63,550	59,475
Denominator	Primary case Patients (= indicator 14a) + Patients with new (local) recurrence and/or distant metastases (= indicator 14b) (without primary M1 pat., since already included in the primary cases)	236.5*	100 – 1,361	90,537	86,481
Rate	Mandatory justification***	72%	1.7% - 100%	70.2%**	68.8%




		2020	2021	2022	2023	2024	Clinical sites with evaluable data				Clinical sites meeting the plausibility limits			
	Max	100%	100%	100%	100%	100%	2024		2023		2024		2023	
	95 th percentile	93.1%	93.5%	90.3%	89.4%	90.1%	314	100%	312	100%	291	92.7%	279	89.4%
	75 th percentile	81.5%	81.4%	80.3%	80.8%	80.3%	Comments: Around 70% of the patients included in the denominator have received advice from social services. 23 clinical sites are required to make a mandatory justification; only 5 of these are located in Germany, whilst the others are abroad, where different regulations regarding social welfare advice or different areas of responsibility apply. For the 5 centres located in Germany, staff shortages (4x) and documentation issues (1x) were cited as reasons.							
	Median	73.7%	73.7%	71.4%	72.7%	72.0%								
	25 th percentile	63.0%	64.6%	61.8%	62.1%	62.0%								
	5 th percentile	32.5%	36.6%	23.0%	21.0%	26.4%								
	Min	0.0%	2.0%	2.8%	1.2%	1.7%								

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.


** Percentage of total patients treated in centres according to the numerator

*** For values outside the plausibility limit(s), the centres are required to provide a justification..

12. Patients enrolled in a study



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Patients who were included in a study with an ethical vote	29.5*	0 – 1,033	18,719	17,867
Denominator	Primary cases	203.5*	68 – 1,213	76,819	73,505
Rate	Target value ≥ 5%	13.2%	0% - 219.9%	24.4%**	24.3%



	2020	2021	2022	2023	2024
Max	236.6%	290.1%	232.8%	236.2%	219.9%
95 th percentile	57.4%	55.5%	62.3%	64.0%	74.0%
75 th percentile	21.5%	23.1%	24.5%	25.8%	26.6%
Median	10.7%	11.9%	12.4%	14.2%	13.2%
25 th percentile	6.2%	6.7%	7.0%	6.8%	7.5%
5 th percentile	1.3%	2.9%	2.8%	3.3%	4.3%
Min	0.0%	0.0%	0.0%	0.0%	0.0%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
314	100%	312	100%	294	93.6%	286	91.7%
Comments: The target value for the proportion of study patients is ≥ 5% and was met by around 94% of clinical sites. Around a quarter of primary cases were enrolled in trials with ethical approval. 20 clinical sites fell short of the target value: reasons cited included trials that were coming to an end or had not yet opened, delays in recruiting new trials, and the inability to enrol patients due to patient-related exclusion criteria. A deviation was noted at 3 clinical sites.							

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centres according to the numerator.

Individual Annual Report - Benchmark

Individual Annual Report - Evaluation of site-specific key figures


What is the individual Annual Report?

In the individual annual report, the site-specific centre data is shown and compared to the other certified centres in the respective certification system of the German Cancer Society. In addition, the individual development of the centre is presented over the course of time.

The content and design of an individual Annual Report are based on the general Annual Reports. An example of an individual Annual Report is available at www.onkoziert.de under General Information / Annual Reports.

Who can receive the individual Annual Report?

The prerequisite for the preparation of the individual annual report is the publication of the general annual report (announcement on www.onkoziert.de) as well as the depiction of the own centre in the general Annual Report (for example, centres with initial certification are not depicted in the audit year). In the case of multi-site centres, each site is shown in its own individual Annual Report. Only the general Annual Report is currently available for oncology centres.



Example centre (red bar) compared to the other certified centres

	Indicator definition	Example centre				
		2020	2021	2022	2023	2024
Numerator	Patients referred by the denominator who received inpatient or outpatient counselling from social services	185	198	176	170	186
Denomintor	Primary cases (= indicator 1a) + patients with newly occurring recurrence (local, regional LN metastases) and/or distant metastases (= indicator 1b)	305	338	333	335	305
Rate	Mandatory justification*** <20%	60,66%	58,58%	52,85%	50,75%	60,98%

Individual development of the example centre over time

**Extract from an individual Annual Report
(indicator counselling social service)**

Individual Annual Report - Benchmark

How can I receive the individual Annual Report?

The individual Annual Report is made available for download as an electronic PowerPoint file on the [Data-WhiteBox](#) platform.

Access to an individual Annual Report differs depending on the certification system:


Colorectal, Prostate and Gynaecological Cancer Centres

- The individual Annual Report is made available for all Colorectal, Prostate and Gynaecological Cancer Centres by decision of the respective Certification Commission.
- The centres (centre management and centre coordination) are informed by email by OnkoZert about the availability of the respective individual Annual Report.
- The centres (centre management and centre coordination) are informed by email by OnkoZert about the availability of the respective individual Annual Report.


All other Organ Cancer Centres / Modules

- The centres (centre management and centre coordination) are informed by email by OnkoZert about the basic availability of the individual Annual Reports. From this point onwards, an individual Annual Report can optionally be ordered for a fee.
- The 'Individual Annual Report Order Form' is available at www.onkozert.de under General Information / Annual Reports. Orders can only be placed by persons who are registered with OnkoZert as contact persons (e.g. centre management, centre coordination, QMB, etc.)
- The costs for the respective individual Annual Reports are listed on the form.
- The preparation time is approx. 3 weeks after receipt of order.

13. Pretherapeutic histological confirmation (GL QI)




	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Primary cases of the denominator with pretherapeutic histological diagnosis confirmation by punch or vacuum-assisted biopsy	166.5*	54 - 1110	63,173	60,624
Denominator	Primary cases with initial surgery and histology of invasive breast cancer or DCIS	169*	54 – 1,134	64,190	61,675
Rate	Target value ≥ 90%	99%	86.8% - 100%	98.4%**	98.3%



*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.


** Percentage of total patients treated in centres according to the numerator.

14a. Primary cases breast cancer




Sollvorgabe = target value

	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Number	Primary Cases	203.5	68 – 1,213	76,819	73,505
	Target value ≥ 100				




		2020	2021	2022	2023	2024	Clinical sites with evaluable data				Clinical sites meeting the target value			
	Max	916	964	1,101	1,153	1,213	2024		2023		2024		2023	
	95 th percentile	439.3	451.5	454.3	475.7	504.5	314	100%	312	100%	308	98.1%	303	97.1%
	75 th percentile	256.5	269.3	273.3	283.3	289.8	Comments: 98% of the clinical sites meet the target value for this indicator and have ≥ 100 primary cases. The median stands at approximately 204 primary cases and continues to rise over the years. The 6 sites that fell short of the target value were subject to a surveillance audit. The reasons cited included changes in senior management and the provision of care in a regionally competitive environment. 3 centres referred to the grandfathering clause, which applies to two cooperating clinical sites with > 150 cases per year. In 2024, a transitional arrangement of 50 procedures per clinical site still applied under the G-BA minimum volume regulation for the surgical treatment of breast cancer.							
	Median	180	187.5	185.5	198.5	203.5								
	25 th percentile	132.5	142	140.8	143	148.8								
	5 th percentile	89.1	94.5	92.4	106.6	107								
	Min	49	53	53	52	68								

14b. Patients with 1st (local) recurrence and/or distant metastases (without primary M1 patients)




	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Number	Patients with new (local) recurrence and/or distant metastases (without primary M1 Pat.)	35	2 - 209	13,718	12,976
	No target value				




		2020	2021	2022	2023	2024	Clinical sites with evaluable data		Clinical sites meeting the target value	
	Max	188	173	192	198	209	2024		2023	
	95 th percentile	85	94	97.7	106.5	111	314	100%	312	100%
	75 th percentile	49	47	49	52	54.8	---	---	---	---
	Median	30	31	32	36	35				
	25 th percentile	19	19	21	21	23				
	5 th percentile	9	9	11	9	11				
	Min	2	3	1	1	2				
Comments: The median number of patients with a new (local) recurrence and/or distant metastases (excluding patients with primary M1 disease) lies within a wide range (2–209) and is roughly on a par with the previous year (n=35).										

15. Number of surgical procedures for R0 resection for Breast Conserving Procedure (BCT) Certification



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Primary cases of the denominator with only one surgical procedure up to final surgical condition BCT	109.5*	33 - 739	41,729	39,730
Denominator	Surgical primary cases with BCT and R0	124.5*	37 - 837	46,980	44,881
Rate	Mandatory justification*** < 70%	89%	70.2% - 100%	88.8%**	88.5%



	2020	2021	2022	2023	2024
Max	100%	100%	100%	100%	100%
95 th percentile	97.7%	97.1%	97.7%	97.4%	97.1%
75 th percentile	92.0%	92.8%	92.7%	92.6%	93.4%
Median	87.6%	87.6%	88.5%	88.6%	89.0%
25 th percentile	82.4%	83.3%	83.6%	84.2%	84.7%
5 th percentile	75.9%	77.1%	77.4%	77.3%	78.3%
Min	65.2%	57.9%	68.9%	66.5%	70.2%

Clinical sites with evaluable data				Clinical sites meeting the plausibility limits			
2024		2023		2024		2023	
314	100%	312	100%	314	100%	310	99.4%

Comments:


In approximately 89% of primary cases treated with BCT, an R0 resection was achieved in a single surgical procedure. Whereas two centres were required to provide justification in the previous year, in the current indicator year all centres are above the lower plausibility threshold of < 70%.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.


** Percentage of total patients treated in centres according to the numerator

*** For values outside the plausibility limit(s), the centres are required to provide a justification..

16. Breast-conserving procedure for pT1 (incl. (y)pT1 u. (y)pT0)



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Primary cases of the denominator with BCT (final surgical condition)	77*	19 - 621	30,258	28,831
Denominator	Surgical primary cases with pT1 (incl. (y)pT1) a. (y)pT0)	94.5*	26 - 780	36,703	34,987
Rate	Target value ≥ 70 %	84.1%	41.7% - 97.6%	82.4%**	82.4%




		2020	2021	2022	2023	2024	Clinical sites with evaluable data		Clinical sites meeting the target value			
	Max	----	----	----	100%	97.6%	2024	2023	2024	2023	2024	2023
	95 th percentile	----	----	----	94.4%	93.2%	314	100%	312	100%	299	95.2%
	75 th percentile	----	----	----	88.2%	88.2%					295	94.6%
	Median	----	----	----	83.6%	84.1%						
	25 th percentile	----	----	----	78.8%	79.0%						
	5 th percentile	----	----	----	69.5%	70.1%						
	Min	----	----	----	37.0%	41.7%						
Comments: As in the previous indicator year, approximately 82% of primary cases classified as pT1 (including (y)pT1 and (y)pT0) underwent breast-conserving surgery. 15 clinical sites performed breast-conserving surgery in fewer than 70% of these primary cases: reasons included the patient's preference, multicentricity, inflammatory carcinoma, pathogenic germline variants and contraindications to adjuvant radiotherapy. One deviation was noted.												


*The median for numerator and denominator does not refer to an existing centre but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

** Percentage of total patients treated in centres according to the numerator.

17. Mastectomies



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Primary cases of the nominator with mastectomies (final surgical stage)	42.5*	7 - 313	16,711	16,220
Denominator	Surgical primary cases	169*	54 – 1,134	64,190	61,675
Rate	Mandatory justification*** <15% and >40%	25.5%	10.4% - 63.9%	26%**	26.3%




		2020	2021	2022	2023	2024	Clinical sites with evaluable data				Clinical sites within the plausibility limits			
	Max	49.5%	49.1%	77.4%	67.3%	63.9%	2024		2023		2024		2023	
	95 th percentile	39.5%	39.5%	39.7%	41.0%	39.5%	314	100%	312	100%	280	89.2%	273	87.5%
	75 th percentile	32.4%	31.7%	30.6%	30.4%	31.0%	Comments: In around a quarter of primary cases requiring surgery, a mastectomy was performed. The median rate has remained at a similar level over the years. However, there are variations in mastectomy rates between clinical sites, ranging from 10-64%. 20 clinical sites with a rate of < 15% and 14 with a rate of > 40% are required to make a mandatory justification. The clinical sites with low mastectomy rates attributed this, amongst other things, to a high proportion of patients with early-stage tumours and close collaboration with regional screening units. For rates > 40%, reasons cited included the patient's wishes (need for reassurance, avoidance of radiotherapy), multifocal/multicentric findings, the presence of a genetic mutation, and the tumour size to breast size ratio. Remarks were made during the audits, but no non-conformities were identified.							
	Median	27.0%	25.5%	26.0%	25.7%	25.5%								
	25 th percentile	20.8%	20.8%	20.9%	21.1%	20.4%								
	5 th percentile	13.7%	14.8%	14.7%	14.0%	14.4%								
	Min	6.7%	7.6%	4.7%	4.2%	10.4%								

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.


** Percentage of total patients treated in centres according to the numerator

*** For values outside the plausibility limit(s), the centres are required to provide a justification..

18. Lymph node removal in the case of DCIS (GL QI)



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Primary cases of the denominator with axillary lymph node removal (primary axillary lymph node removal or sentinel lymph node removal)	0*	0 - 5	127	132
Denominator	Primary cases DCIS with completed surgical therapy and BCT	14*	1 - 103	5,529	5,314
Rate	Target value ≤ 5%	0%	0% - 50%	2.3%**	2.5%




		2020	2021	2022	2023	2024	Clinical sites with evaluable data		Clinical sites meeting the target value			
							2024	2023	2024	2023	2024	2023
	Max	50.0%	57.1%	50.0%	50.0%	50.0%	314	100%	310	99.4%	261	83.1%
	95 th percentile	18.8%	19.5%	16.7%	13.3%	14.3%					246	79.4%
	75 th percentile	5.3%	5.3%	4.0%	3.9%	3.3%						
	Median	0.0%	0.0%	0.0%	0.0%	0.0%						
	25 th percentile	0.0%	0.0%	0.0%	0.0%	0.0%						
	5 th percentile	0.0%	0.0%	0.0%	0.0%	0.0%						
	Min	0.0%	0.0%	0.0%	0.0%	0.0%						
Comments: Around 2% of primary DCIS cases that have undergone complete surgical treatment and BCT have had axillary lymph node removal (primary axillary lymph node removal or sentinel lymph node removal). As in previous indicator years, the median stands at 0%. 83% of clinical sites meet the target value; 53 clinical sites performed axillary lymph node removal in > 5% of cases. In particular, clinical sites with high rates had small case numbers. The results were reviewed during the audits, deemed plausible, and no deviations were identified.												


*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

** Percentage of total patients treated in centres according to the numerator.

19. Determination of nodal status in case of invasive breast cancer



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Primary cases of the denominator for which nodal status was determined	140*	48 - 895	52,817	51,993
Denominator	Surgical primary cases with invasive breast cancer (without primary M1)	147*	51 - 955	55,791	53,800
Rate	Target value ≥ 95%	96.1%	66% - 100%	94.7%**	96.6%




	2020	2021	2022	2023	2024
Max	100%	100%	100%	100%	100%
95 th percentile	100%	100%	100%	100%	100%
75 th percentile	98.8%	98.8%	98.7%	98.8%	98.0%
Median	97.5%	97.5%	97.5%	97.5%	96.1%
25 th percentile	95.9%	96.0%	95.9%	95.8%	93.5%
5 th percentile	93.2%	92.8%	92.6%	91.5%	84.9%
Min	89.5%	85.1%	85.0%	77.6%	66.0%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
314	100%	312	100%	200	63.7%	257	82.4%


Comments:
In 95% of primary cases of invasive breast cancer (excluding primary M1) that underwent surgery, the nodal status was determined. Around 64% of clinical sites meet the target value of ≥ 95% for this indicator. At the 2025 meeting of the Certification Commission, it was decided to remove this indicator, following a change in the recommendations based on findings from various studies (including SOUND and INSEMA). The indicator is therefore reported here for the last time.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centres according to the numerator.

20a. Only sentinel lymphonodectomy (SLNE) for pN0 (women) (GL QI)




	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Primary cases of the denominator with only sentinel lymph node removal (SNB)	70*	10 - 511	25,716	26,156
Denominator	Female primary cases of invasive breast cancer with negative pN staging and without preoperative tumour-specific therapy	75*	11 - 535	27,544	28,098
Rate	Target value $\geq 80\%$	95%	49.8% - 100%	93.4%**	93.1%




		2020	2021	2022	2023	2024	Clinical sites with evaluable data		Clinical sites meeting the target value			
							2024	2023	2024	2023	2024	2023
	Max	100%	100%	100%	100%	100%	314	100%	312	100%	306	97.5%
	95 th percentile	100%	100%	100%	100%	100%					307	98.4%
	75 th percentile	98.2%	98.1%	97.5%	98.0%	98.4%						
	Median	94.9%	95.5%	94.5%	94.7%	95.0%						
	25 th percentile	90.1%	90.9%	90.0%	88.9%	90.1%						
	5 th percentile	83.3%	84.4%	83.0%	83.3%	82.6%						
		Min	37.0%	7.3%	70.8%	65.7%						
Comments: The median for indicator 20a has remained constant at 95% for years, whilst that for indicator 20b has been 100%. The recommendations based on findings from studies into the procedure have changed. The BC Certification Commission therefore decided at its 2025 meeting to remove both SNB indicators (indicator 20a/b) from the set of indicators, meaning that they are reported here for the last time.												

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centres according to the numerator.

20b. Only sentinel lymphonodectomy (SLNE) for pN0 (men) (GL QI)



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Primary cases of the denominator with only sentinel lymph node removal (SNB)	1*	0 - 86	297	200
Denominator	Male primary cases of invasive breast cancer with negative pN staging and without preoperative tumour-specific therapy	1*	1 - 104	329	217
Rate	Target value ≥ 80%	100%	0% - 100%	90.3%**	92.2%




	2020	2021	2022	2023	2024
Max	100%	100%	100%	100%	100%
95 th percentile	100%	100%	100%	100%	100%
75 th percentile	100%	100%	100%	100%	100%
Median	100%	100%	100%	100%	100%
25 th percentile	100%	100%	100%	100%	100%
5 th percentile	16.7%	50.0%	0.0%	50.0%	36.7%
Min	0.0%	0.0%	0.0%	0.0%	0.0%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
152	48.4%	144	46.2%	141	92.8%	127	88.2%


Comments:
At 162 clinical sites, no male primary cases of invasive breast cancer with negative pN staging and without pre-operative tumour-specific treatment were treated during the year under review. Of the clinical sites with patients from the population under review, approximately 93% met the target value. At its meeting in 2025, the BC Certification Commission decided to remove this indicator from the set of indicators, meaning that it is reported here for the last time.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centres according to the numerator.

21. Intraoperative sample radiography / sonography (GL QI)



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Surgical procedures of the denominator with intraoperative sample x-ray or with intraoperative sample sonography	96*	1 - 774	37,523	35,730
Denominator	Surgical procedures with preoperative wire marking guided by mammography or sonography	97*	1 - 775	37,784	36,004
Rate	Target value ≥ 95%	100%	88.1% - 100%	99.3%**	99.2%




		2020	2021	2022	2023	2024	Clinical sites with evaluable data		Clinical sites meeting the target value	
							2024	2023	2024	2023
	Max	100%	100%	100%	100%	100%	314	100%	311	99.7%
	95 th percentile	100%	100%	100%	100%	100%			311	99%
	75 th percentile	100%	100%	100%	100%	100%			308	99%
	Median	100%	100%	100%	100%	100%				
	25 th percentile	99.2%	99.6%	99.4%	99.3%	99.1%				
	5 th percentile	96.4%	96.5%	96.6%	96.5%	96.4%				
	Min	82.6%	81.3%	90.2%	83.9%	88.1%				
Comments: The indicator continues to be met at a high level by the centres: median 100% ; 99% of clinical sites met the target value. In 99% of operations involving pre-operative wire marking guided by mammography or ultrasound, intraoperative radiography or intraoperative ultrasound was performed. 3 centres fell short of the target value. Remarks were issued; no deviations were identified.										


*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

** Percentage of total patients treated in centres according to the numerator.

22. Revision surgeries



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Primary cases of the denominator with revision surgeries as a consequence of postoperative complications (only surgical primary cases)	3*	0 - 39	1,461	1,474
Denominator	Primary cases who underwent surgery	169*	54 – 1,134	64,190	61,675
Rate	Target value ≤ 5%	1.9%	0% - 8.9%	2.3%**	2.4%




	2020	2021	2022	2023	2024
Max	13.8%	9.4%	9.3%	9.4%	8.9%
95 th percentile	5.8%	5.1%	5.2%	5.4%	5.0%
75 th percentile	3.9%	3.5%	3.3%	3.4%	3.3%
Median	2.6%	2.1%	2.2%	2.2%	1.9%
25 th percentile	1.4%	1.2%	1.2%	1.1%	1.1%
5 th percentile	0.4%	0.0%	0.0%	0.0%	0.0%
Min	0.0%	0.0%	0.0%	0.0%	0.0%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
314	100%	312	100%	299	95.2%	290	92.9%


Comments:
Revision surgery was required as a result of post-operative complications in only around 2.3% of primary cases that underwent surgery. At 17 clinical sites, not a single revision operation was required. The median is 1.9%. 15 clinical sites had a revision rate of > 5%. The main indications cited for revisions were post-operative bleeding, haematomas, impaired wound healing, infections and seromas.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centres according to the numerator.

23. Therapy of the axillary lymphatic drainage for pN1mi (GL QI)



	Definition of indicator	All clinical sites 2024			2023
		Median	Range	Patients Total	Patients Total
Numerator	Primary cases of the denominator with therapy (axillary dissection or radiotherapy) of the axillary lymphatic drainage	0*	0 - 3	73	84
Denominator	Primary cases invasive breast cancer, pN1mi without neoadj. chemotherapy)	3*	1 - 35	1,143	1,146
Rate	Target value ≤ 5%	0%	0% - 100%	6.4%**	7.3%



		2020	2021	2022	2023	2024
Max		----	100%	100%	100%	100%
95 th percentile		----	50.0%	50.0%	50.0%	50.0%
75 th percentile		----	0.0%	0.0%	0.0%	0.0%
Median		----	0.0%	0.0%	0.0%	0.0%
25 th percentile		----	0.0%	0.0%	0.0%	0.0%
5 th percentile		----	0.0%	0.0%	0.0%	0.0%
Min		----	0.0%	0.0%	0.0%	0.0%

Clinical sites with evaluable data				Clinical sites meeting the target value			
2024		2023		2024		2023	
280	89.2%	274	87.8%	224	80%	215	78.5%

Comments:
In the indicator year, no primary cases from the population covered by the indicator were treated at 34 clinical sites. Of the remaining 280 clinical sites, 80% met the target value, with 223 clinical sites (approximately 80%) even achieving a rate of 0%. 56 clinical sites recorded rates > 5%. The cases were critically discussed during the audits and, in the vast majority of instances, were found to be plausible. This was the last time the indicator was collected, as the Certification Commission decided at its 2025 meeting to remove it from the set of indicators.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centres according to the numerator.

Find out more on www.krebsgesellschaft.de

Authors

German Cancer Society (DKG)
German Society for Senology (DGS)
Certification Committee Breast Cancer Centres
Jens-Uwe Blohmer, Spokesman Certification Committee
Achim Wöckel, Spokesman Certification Committee
Martin Utzig, German Cancer Society (DKG)
Birgit Klages, German Cancer Society (DKG)
Ellen Griesshammer, German Cancer Society (DKG)
Katharina Lepique, German Cancer Society (DKG)
Agnes Bischofberger, OnkoZert
Florina Dudu, OnkoZert

Imprint

Publisher and responsibility regarding content:
Deutsche Krebsgesellschaft (DKG)
Kuno-Fischer-Straße 8
DE 14057 Berlin, Germany
Tel: +49 (030) 322 93 29 0
Vereinsregister Amtsgericht Charlottenburg,
Vereinsregister-Nr.: VR 27661 B
V.i.S.d.P.: Dr. Konstanze Blatt

in cooperation with:
OnkoZert, Neu-Ulm
www.onkozert.de

Version e-A1-en; Stand 30.06.2026

ISBN: 978-3-912231-29-8

